Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
McNaughton AL, Paton RS, Edmans M, Youngs J, Wellens J, Phalora P, Fyfe A, Belij-Rammerstorfer S, Bolton JS, Ball J, Carnell GW, Dejnirattisai W, Dold C, Eyre DW, Hopkins P, Howarth A, Kooblall K, Klim H, Leaver S, Lee LN, López-Camacho C, Lumley SF, Macallan DC, Mentzer AJ, Provine NM, Ratcliff J, Slon-Compos J, Skelly D, Stolle L, Supasa P, Temperton N, Walker C, Wang B, Wyncoll D; Oxford Protective T Cell Immunology for COVID-19 (OPTIC) consortium; Scottish National Blood Transfusion Service (SNBTS) consortium; Simmonds P, Lambe T, Baillie JK, Semple MG, Openshaw PJ; International Severe Acute Respiratory and emerging Infection Consortium Coronavirus Clinical Characterisation Consortium (ISARIC4C) investigators; Obolski U, Turner M, Carroll M, Mongkolsapaya J, Screaton G, Kennedy SH, Jarvis L, Barnes E, Dunachie S, Lourenço J, Matthews PC, Bicanic T, Klenerman P, Gupta S, Thompson CP.
McNaughton AL, et al. Among authors: jarvis l.
JCI Insight. 2022 Jul 8;7(13):e156372. doi: 10.1172/jci.insight.156372.
JCI Insight. 2022.
PMID: 35608920
Free PMC article.